Medicore, Inc. Reports 2001 Results.

Business Editors

HIALEAH, Fla.--(BUSINESS WIRE)--April 1, 2002

Medicore, Inc. (Nasdaq:MDKI) announced 2001 revenues from continuing operations of $20,691,000 with a net loss of $(339,000) compared to revenues from continuing operations of $10,797,000 with a net loss of $(776,000) for the prior year. Net income, including discontinued operations, was $1,232,000 or $.20 per share for 2001 compared to a net loss of $(406,000) or $(.07) per share for 2000. Discontinued operations, representing our former electro-mechanical operations, in which we sold our interest in June 2001, included a net loss from operations of $(963,000) for 2001 compared to net income of $369,000 for 2000, and a gain on disposal of these operations of $2,535,000 for 2001.

Thomas K. Langbein, Chief Executive Officer and President commented, "Our majority owned subsidiary, Dialysis Corporation of America (`DCA') more than doubled its sales revenues during 2001 compared to 2000 and became profitable during 2001. We are very pleased with the results of DCA's controlled expansion. The sale of our interest in our former electro-mechanical manufacturing operations will enable us to place more emphasis on the expansion of DCA. DCA opened three new kidney dialysis centers during 2001 and another in January 2002, and is currently developing two additional centers and in the process of acquiring another center. DCA intends to continue efforts at development and acquisition of additional dialysis centers.

"We remain enthusiastic about our new technology division which invests in and incubates new technology. We believe our investment in Linux Global Partners, which invests in Linux software companies, continues to offer potential as Linux continues to establish itself as an alternative to current major operating systems."

The company is engaged in the operation of kidney dialysis centers through DCA, which has eleven centers in Pennsylvania, New Jersey and Georgia, and a 40% interest in an Ohio center, which it also manages. The company also distributes medical products and invests in and incubates technology companies.

This release contains forward-looking statements that are subject to risks and uncertainties, including but not limited to, general economic conditions, DCA's ability to develop or acquire additional dialysis facilities, regulation of dialysis operations, government rate determination for Medicare reimbursement, the highly competitive environment in the operation and acquisition of dialysis centers and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.

                    MEDICORE, INC. AND SUBSIDIARIES

                 CONSOLIDATED STATEMENTS OF OPERATIONS

Revenues                           2001         2000         1999
 Sales:
  Product sales                 $   861,077  $ 1,112,366  $ 1,119,180
  Medical service revenues       18,919,752    8,769,470    5,498,541
                                -----------  -----------  -----------
     Total sales                 19,780,829    9,881,836    6,617,721
  Gain on subsidiary warrants
   exercise                             ---      276,178          ---
  Realized gain on sale of
   marketable securities                ---          ---      263,144
  Other income                      910,264      638,646      626,591
                                -----------  -----------  -----------
                                 20,691,093   10,796,660    7,507,456
Cost and expenses:
 Cost of sales:
  Cost of product sales             775,969      949,939      837,109
  Cost of medical services       12,021,907    5,833,081    3,964,258
                                -----------  -----------  -----------
     Total cost of sales         12,797,876    6,783,020    4,801,367
  Selling, general and
   administrative expenses        7,869,714    4,588,776    3,789,419
  Provision for doubtful
   accounts                         661,158      195,244      101,399
  Interest expense                  228,312       97,923       78,792
                                -----------  -----------  -----------
                                 21,557,060   11,664,963    8,770,977
                                -----------  -----------  -----------
Loss from continuing operations
 before income taxes, minority
 interest and equity in affiliate
 loss                              (865,967)    (868,303)  (1,263,521)

Income tax (benefit) provision     (928,125)      23,061     (292,462)
                                -----------  -----------  -----------

Income (loss) from continuing
 operations before minority
 interest and equity in affiliate
 loss                                62,158     (891,364)    (971,059)

Minority interest in income
 (loss) of consolidated
 subsidiaries                       385,233     (136,534)    (213,510)

Equity in affiliate loss            (16,345)     (20,896)         ---
                                -----------  -----------  -----------
Net loss from continuing
 operations                        (339,420)    (775,726)    (757,549)

Discontinued operations:
(Loss) income from operations of
 electro-mechanical manufacturing
 operations, net of applicable
 income taxes of $25,000 in 2001,
 $91,000 in 2000 and $350,000 in
 1999                              (962,814)     369,292      144,492
Gain on disposal of
 electro-mechanical manufacturing
 operation, net of applicable
 income taxes of $1,621,000       2,534,656          ---          ---
                                -----------  -----------  -----------
Net income (loss)               $ 1,232,422  $  (406,434) $  (613,057)
                                ===========  ===========  ===========

Earnings (loss) per share:
   Basic                               $.20        $(.07)       $(.11)
                                       ====        =====        =====
   Diluted                             $.20        $(.07)       $(.11)
                                       ====        =====        =====